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The gastrointestinal tract is a complex and dynamic network where an intricate and mutualistic symbiosis
modulates the relationship between the host and the microbiota in order to establish and ensure gut homeostasis.
Commensal Clostridia consist of gram-positive, rod-shaped bacteria in the phylum Firmicutes and make up a
substantial part of the total bacteria in the gut microbiota. They start to colonize the intestine of breastfed infants
during the first month of life and populate a specific region in the intestinal mucosa in close relationship with
intestinal cells. This position allows them to participate as crucial factors in modulating physiologic, metabolic and
immune processes in the gut during the entire lifespan, by interacting with the other resident microbe populations,
but also by providing specific and essential functions. This review focus on what is currently known regarding the
role of commensal Clostridia in the maintenance of overall gut function, as well as touch on their potential
contribution in the unfavorable alteration of microbiota composition (dysbiosis) that has been implicated in several
gastrointestinal disorders. Commensal Clostridia are strongly involved in the maintenance of overall gut function.
This leads to important translational implications in regard to the prevention and treatment of dysbiosis, to drug
efficacy and toxicity, and to the development of therapies that may modulate the composition of the microflora,
capitalizing on the key role of commensal Clostridia, with the end goal of promoting gut health.
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The gastrointestinal (GI) tract, man’s most widely ex-
posed organ system to the external environment with a
global surface of 200 m2, is a complex and dynamic net-
work with interplay between various gut mucosal cells
and their defense molecules, the immune system, food
particles, and the resident microbiota. This ecosystem
acts as a functional unit organized as a semipermeable
multi-layer system that allows the absorption of nutri-
ents and macromolecules required for human metabolic
processes and, on the other hand, protects the individual
from potentially invasive microorganisms [1,2]. These
basic functions are carried out in a dynamic environ-
ment inhabited by 1kg of commensal microbes that in-
clude more than 3mln of genes [3,4]. They belong to the
three domains of life, Bacteria, Archaea and Eukarya
[5-7], as well as to viral particles [8,9]. Recent advances* Correspondence: lopetusoloris@libero.it
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reproduction in any medium, provided the orin culture-independent molecular techniques, by the ana-
lysis of phylogenetic arrays, next generation 16S rRNA
sequencing and metagenome sequencing derived from
human mucosal biopsies, luminal contents and feces,
have shown that four major microbial phyla, (Firmicutes,
Bacteroides, Proteobacteria and Actinobacteria), represent
98% of the intestinal microbiota and fall into three main
groups of strict extremophile anaerobes: Bacteroides,
Clostridium cluster XIVa (also known as the Clostridium
Coccoides group), and Clostridium cluster IV (also known
as the Clostridium leptum group) [5,6,10-17].
An intricate and mutualistic symbiosis modulates the
relationship between the host and the gut microbiota
[11,18,19]. This relationship is constantly challenged with
several factors such as rapid turnover of the intestinal epi-
thelium and overlaying mucus, exposure to peristaltic
activity, food molecules, gastric, pancreatic and biliary se-
cretions, defense molecules, drugs, pH and redox poten-
tial variations, and exposure to transient bacteria from
the oral cavity and esophagus, and can lead to the col-
lapse of the microbial community structure [17]. On theal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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functions, including maintaining barrier function, synthe-
sis and metabolism of nutrients, drug and toxin metabol-
ism, and behavioral conditioning [20]. Gut microbiota is
also involved in the digestion of energy substrates, pro-
duction of vitamins and hormones [21], protection from
pathogenic bacteria by consuming nutrients and produ-
cing molecules that inhibit their growth [22-24], produc-
tion of nutrients for mucosal cells [25-27], augmenting
total and pathogen-specific mucosal IgA levels upon in-
fection [28,29], and in modulating immune system devel-
opment and immunological tolerance [30].
Unfavorable alteration of microbiota composition, known
as dysbiosis, has been implicated in chronic gut, and per-
haps also systemic, immune disorders, such as in the patho-
genesis of inflammatory bowel diseases (IBD), and other
gastrointestinal disorders, including gastritis, peptic ulcer,
irritable bowel syndrome (IBS) and even gastric and colon
cancer [14,31-33].
In this scenario, gut commensal Clostridia consist
of gram-positive, rod-shaped bacteria in the phylum
Firmicutes. The Clostridium cluster XIVa and IV, known
for many years as fusiform-shaped bacteria, make up a
substantial part (10-40%) of the total bacteria in the gut
microbiota [10,14,17]. As such, it is likely that Clostridia
play a crucial role in gut homeostasis by interacting with
the other resident microbe populations, but also by pro-
viding specific and essential functions. The purpose of
this review is to explore and emphasize the critical role
of intestinal commensal Clostridia in modulating normal
gut homeostasis. Based on this, detailed mechanistic stud-
ies could improve the development of microbial therapies
that may modulate the composition of the gut microflora,
capitalizing on the key role of commensal Clostridia, with
the end goal of promoting gut health.
Gut barrier and commensal microbiota
The intestinal barrier is a functional unit, organized as a
multi-layer system, in which it is possible to recognize
two main parts: a superficial physical barrier, which pre-
vents bacterial adhesion and regulates paracellular diffu-
sion to the underlying host tissues, and a deeper functional
barrier, which is able to discriminate commensal bacteria
from pathogens and is responsible for immunological tol-
erance to commensal and immune response to pathogen
microorganisms [20]. Everyday, thousands of compounds
derived from food and microorganisms come in contact
with the intestinal mucosa. This interaction requires a
complex defense system that separates intestinal contents
from the host tissues, regulates nutrient absorption, and
allows tolerance between the resident bacterial flora and
the mucosal immune system, while inhibiting transloca-
tion of infectious agents to the inner tissues. Commensal
gut microbiota constitutes the anatomical barrier, alongwith the mucous layer and the intestinal epithelial mono-
layer. The deeper, inner layer consists of a complex
network of immune cells organized in a specialized
and compartmentalized system known as “gut-associated
lymphoid tissue” or GALT. GALT represents both iso-
lated and aggregated lymphoid follicles and is one of the
largest lymphoid organs, containing up to 70% of the
body’s total number of immunocytes and is involved in
responding to pathogenic microorganisms, as well as
providing immune tolerance to commensal bacteria. The
ability of GALT to interact with the luminal antigens rests
on specific mucosal immune cells (i.e., dendritic cells and
M-cells), primarily localized to Peyer’s patches within the
ileum that are intimately positioned at the mucosal-
environmental interface and internalize microorganisms
and macromolecules. These specialized immune cells have
the ability to present antigen to naïve T-lymphocytes,
which subsequently produce cytokines and activate muco-
sal immune responses, when needed. Thus, the mucosal
immune system participates in the maintenance of gut
microbial communities by directly monitoring the lu-
minal environment through the constant sampling through
M-cells that overlie lymphoid follicles and by dendritic cells
that resides within the lamina propria. The interaction of
these cellular components sustains the delicate equilibrium
to maintain intestinal homeostasis, establishing a state of
immunological tolerance towards antigens from food and
commensal bacteria. Many factors can alter this balance, in-
cluding alterations in the gut microflora, modifications of
the mucus layer, and epithelial damage, leading to increased
intestinal permeability and translocation of luminal con-
tents to the underlying mucosa. Dysregulation of any of the
aforementioned components have been implicated, not
only in the pathogenesis of IBD, but in many other GI dis-
orders, including infectious enterocolitis, IBS, small intes-
tinal bowel overgrowth, celiac sprue, hepatic fibrosis, atopic
manifestations and food intolerance [34-36].
The gut microbiota, which includes Clostridium spp., is
an essential actor in the aforementioned defense mecha-
nisms and in the resistance to infection. It plays a crucial
role, both by acting indirectly, for example in immune
system development and modulating immunological tol-
erance [37], and also directly, by preventing potentially
deleterious and pathogenic organisms from taking up
residence. This phenomenon is known as colonization
resistance [17].
Commensal Clostridia in the GI tract
In healthy adults, each segment of the GI tract is popu-
lated with a distinct and stable community of microbes.
Escherichia, Clostidium, Lactobacillus, Bacteroides, Eu-
bacterium, Peptococcus, Peptostreptococcus, Veillonella,
Fusobacterium and Bifidobacterium are the predominat-
ing microbial genera within the GI tract [38]. The distal
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with an estimated density of 1x1012 organisms per gram
(dry weight) of feces [39]. Recent cultivation-independent
16S rRNA gene next generation sequencing tech-
niques showed that in the colon, the most numeric-
ally predominant organisms belong to three groups
of strict anaerobes: Bacteroides, Clostridium cluster
XIVa and Clostridium cluster IV [10]. The Clostridium
cluster XIVa includes species belonging to the Clostrid-
ium, Eubacterium, Ruminococcus, Coprococcus, Dorea,
Lachnospira, Roseburia and Butyrivibrio genera. Clostrid-
ium cluster IV is composed by the Clostridium, Eubacter-
ium, Ruminococcus and Anaerofilum genera [40]. Clostridia
are gram-positive bacteria; they form endospores and
therefore have an ecological advantage for survival under
adverse conditions. Some Clostridia groups possesses
pathogenic species, such as Clostridium Perfrigens and
Clostridium Tetani, that are members of Clostridium
cluster I, and Clostridium Difficile, a member of cluster XI.
However, most of the Clostridia have a commensal rela-
tionship with the host.
Clostridia start to colonize the human intestine of
breastfed infants during the first month of life [41]. Of
note, infant-type microbiota is extremely plastic [42].
During birth, bacteria from the mother and the environ-
ment colonize the sterile GI tract of neonates. During
the first few days of life, the bacterial flora is usually hetero-
geneous and independent of feeding habits. Clostridium
spp. and other obligate anaerobes, such as Bacteroides spp.,
are rarely isolated. Thereafter, the gradual consump-
tion of oxygen by aerobic microorganisms decreases the
oxidation-reduction potential, providing optimal condi-
tions for a more diversified and stable bacterial flora,
which also includes anaerobic bacteria [43]. The aging
process challenges the stability of microbiota and can
also affect the presence of Clostridium spp. In the eld-
erly (>65 years), most available studies obtained with
molecular methods showed a decrease in the number
of strict anaerobes and an increase in the number of
facultative anaerobes (streptococci, staphylococci, en-
terococci, enterobacteriaceae) [44-47]. These data sug-
gest a decrease in the stability and in the diversity of
the gut microbiota with advancing age [48]. However,
Drago et al., studying 14 Italian centenarians, found a sig-
nificant decrease in the total number of anaerobes com-
pared with younger adults, caused by a lower count of
bifidobacteria and bacteroides, whereas the Clostridium
sensu stricto genus significantly increased [49], suggesting
an indispensable and key role of Clostridia in modulating
gut homeostasis during the entire lifespan.
Interestingly, Clostridia have been reported to colonize
a specific part of the intestinal mucosa. In fact, it has
been assessed that there is a spatial organization and di-
versity of microbes across the intestinal lumen [50]. Theascending colon of healthy mice is characterized by
transverse folds, called the interfold region, that projects
approximately 1mm into the lumen and is oriented per-
pendicular to the fecal stream [51]. Low-power magnifi-
cation showed dense material between the transverse
folds, while the central lumen (digesta region) displayed
the presence of a less dense and less homogenous mater-
ial, including food particles [50]. Higher magnification of
these sections defined the material within the interfold
region as fusiform-shaped bacteria (> 5-10 μm), whereas
rod- and coccoid-shaped bacteria comprised the material
of the digesta region. Laser capture microdissection re-
vealed that the areas between the mucosal folds were
populated by Clostridium cluster XIVa and IV, whereas
the regions of the central lumen were enriched with
Bacteroidaceae, Enterococcaceae and Lactobacillaceae [50].
Structural folds similar to the mouse interfold region are
also found in the human intestine and are called plica
lunaris and plica semilunaris in the small bowel and colon,
respectively [50]. As such, it is possible that commensal
Clostridia populate a specific region in the intestinal mu-
cosa, establishing a close relationship with gut cells in
order to perform critical physiological functions in a co-
operative manner.
Commensal Clostridia and gut homeostasis:
the metabolic point of view
The microbiome, the whole genome of the gut flora that
vastly exceeds the human genome [52], codes several
biochemical pathways that are crucial for human life.
These include the biosynthesis of the essential nutrient
vitamins K and B12, the biotransformation of conjugated
bile acids, the degradation of dietary oxalates, the carbo-
hydrate and amino-acid methabolism, and the caloric
extraction from otherwise indigestible polysaccharides.
Furthermore, stimulation of TLR2 on colonic epithelial
cells with bacterial antigens, such as LPS and peptidogly-
can, initiates tight junction development leading to apical
tightening and sealing and to an increased transepithelial
electrical resistance [53]. Germ-free mouse models, com-
pared to control animals, showed increased mucus accu-
mulation in the cecum, water retention, extended epithelial
cell cycles, and decreased peristalsis in the large intestine
[54]. Clostridium spp., due to their specific position in the
mucosa, impact normal intestinal structure and physiology
and are involved in the pathways of the aforementioned
functions with continuous crosstalk with gut cells. In par-
ticular, commensal Clostridia play an important role in the
metabolic welfare of colonocytes by releasing butyrate as
an end-product of fermentation [55].
The short chain fatty acids (SCFAs), acetate, propionate
and butyrate, non-gaseous fermentation end products of
dietary components that are incompletely digested in
the small intestine, provide a high proportion of the total
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nants [55]. In humans, SCFAs, in particular butyrate, are
less involved in the host’s energy contribution, but instead
seem to be the preferred energy source for colonocytes
[56,57] and have an important influence on colonic health
[58,59]. In fact, the colonic mucosa absorbs 95% of butyr-
ate produced by butyrogenic bacteria, but concentrations
in portal blood are usually undetectable as a result of rapid
utilization. Thus, Clostridium spp. perform most of their
metabolic functions through the release of butyrate that is
essential as fuel for colonocytes. However, butyrate also in-
fluences gene expression through the hyperacetylation of
chromatin through its action as a non-competitive inhibi-
tor of histone deacetylases [60]. Moreover, butyrate inhibits
the activation of the transcription factor, NF-kB, leading to
decreased expression of proinflammatory cytokines and to
a consequent anti-inflammatory effect [61,62]. Butyrate has
also been implicated in protection against colitis and colo-
rectal cancer [63-65]. In fact, butyrate has been shown to
induce apoptosis in tumor cells in vitro [66] and, although
colon carcinoma cells overexpress cyclooxygenase 2 and
impart resistant to butyrate-induced apoptosis, it can act as
a suppressing factor for pre-cancerous cells at an earlier
stage of progression [60]. Depending on its concentration,
butyrate is able to inhibit growth, but can also work as a
trophic factor, inducing differentiation of human cells in
tissue culture and preventing or ameliorating conditions,
such as ulcerative colitis [58-60,65,67]. Harmful condi-
tions that lead to a lack of energy supply to colonocytes,
70% of which is normally provided by butyrate, can be a
causative factor in colitis and several reviews discuss its
role in increasing the risks of both colorectal cancer and
IBD [60,65,67]. In an animal model of colitis in which
mice are orally administered dextran sodium sulfate (DSS),
a T-cell independent colitis is induced that results in epi-
thelial damage and acute inflammation, primarily driven by
innate immune responses. Several potential mechanisms
have been proposed to explain DSS-induced colitis. It
could occur by inhibiting butyrate oxidation through sul-
fide toxicity, without affecting glucose metabolism, with
a consequent inadequate energy supply to gut cells from
butyrate [68,69].
Butyrate production is widely distributed among anaer-
obic bacteria belonging to the Clostridial subphylum and
in particular, to the Clostridial clusters XIVa and IV, such
as some potentially important butyrate producers related
to Roseburia and F. prausnitzii that display Butyryl CoA:
acetate CoA transferase activity [70]. However, very little
information exists on the genetic predisposition and regu-
lation of butyrate pathway enzymes in gut Clostridia. Most
of the available data comes from industrial interest in
solventogenic clostridia. More information could be helpful
in developing prebiotic or probiotic strategies to take ad-
vantage of these essential metabolic roles of gut Clostridia.Commensal Clostridia and gut homeostasis:
the brain-gut axis
Interestingly, a recent paper reported that gnotobiotic
mice, associated with a mixture of 46 related Clostridium
spp. from the Coccoides and Leptum groups, showed a
drastic elevation of biologically active, free catecholamines,
including Norepinephrine (NE) and Dopamine (DA), in
the gut lumen compared to germ free mice [71]. Clostridia,
enriched in β-glucuronidase activity, could be responsible
for generating free NE and DA from the glucuronide-
conjugated biologically inactive form that is normally re-
leased in the intestine. The gastrointestinal tract is densely
innervated by noradrenergic and dopaminergic nerves, and
their fibers are found in the gut mucosa, constituting part
of the neuro-enteric system [72]. Catecholamines are uti-
lized in the central and peripheral nervous systems, which
regulate various types of bodily functions, including cogni-
tive abilities, mood [73], immune reactions [74,75], motility
[73], and active water absorption of the intestine [76,77].
This is the first report that indicates a critical role of the
gut microbiota, particularly of commensal Clostridia, in
the generation of free catecholamines in the gut lumen and
open new horizons in the relationship between human
homeostasis and behavior, intestinal physiology and the gut
microbiota.
Crosstalk between Clostridia and gut cells:
the immunological point of view
High levels of metabolites produced by Clostridia and
their colonization in close proximity to the intestinal
mucosa allows us to hypothesize that Clostridia exert a
strong influence on the host immune system. Indeed, it
has been showed that Clostridia can promote the devel-
opment of αβ T cell receptor intraepithelial lymphocytes
(IEL) and immunoglobulin A (IgA)-producing cells in the
large intestine [78]. IEL, IgA-producing cells within the
lamina propria, and intestinal epithelial cells are key players
in determining the nature of the immunological response
to antigens or pathogens ingested. Germ free animals show
a reduced number, low Thy-1 expression, and low cytolytic
activity, of IEL [79,80]. Furthermore, IgA production is rare
[81] and macroscopic Peyer’s patches are small and poorly
developed in comparison with those in conventionally-
housed animals [82]. Umesaki et al. assessed that germ free
mice inoculated with 46 strains of Clostridia singly isolated
from conventional mice showed an increase in the ratio of
CD4- CD8+ cells to that of CD4+ CD8- in αβIEL within the
large intestine. Conversely, the number and phenotype of
IEL were similar to those in conventionally-housed mice.
The number of IgA-producing cells in the colons of mice
treated with Clostridia was slightly increased compared to
that in germ free mice [78]. Thus, Clostridia appear to be
involved in the promotion of immunological development
[78] in the large intestine, but not in the small intestine.
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changes were due to the presence of segmented filamentous
bacteria [78], suggesting the occurrence of compart-
mentalization of the immunological responses to indigen-
ous bacteria and of Clostridia in exerting their specific role
in gut homeostasis. Moreover, commensal Clostridia are
able to normalize cecal size when they are associated with
germ free mice [83]. How the immune system fundamen-
tally senses Clostridia remains unclear. In this context, it
has been suggested that the presence or gradient of SCFAs
and secondary bile acids produced by Clostridia may be
sensed by epithelial cells and in turn, may be associated
with the initiation of immunological signaling [78], due to
the cross talk between epithelial and immune cells. For ex-
ample, IL-7 secreted by epithelial cells can activate IL-7
receptor-bearing IEL on their progenitors [84,85]. Further-
more, IL-6 [86] and transforming growth factor β [87] pro-
duced by the epithelia during infection can stimulate the
development of Peyer’s patches and IgA production [88].
Clostridium spp. belonging to clusters XIV and IV have
also been reported to be strong inducers of colonic T regu-
latory cell (Treg) accumulation [89]. CD4+Foxp3+ Tregs
are the most prominent regulatory cells in the body and
are most abundant in the colonic lamina propria [90,91].
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microbiota [92]. A fraction of intestinal Tregs express T
cell receptors that recognize antigens derived from the gut
microbiota [93]. It has been established that these colonic
Tregs play critical roles in intestinal immune homeostasis,
suppressing systemic and mucosal immune activation
to control intestinal inflammation, and contributing to
maintaining tolerance towards gut microbiota [94,95].
Atarashi et al. showed that colonization of germ free mice
with a defined mixture of 46 Clostridium strains belonging
to clusters XIVa and IV induced the accumulation and dif-
ferentiation of colonic Tregs [89]. Clostridium spp. were
also able to promote increased expression of IL-10 in Treg
[89], expression of matrix metalloproteinases (MMPs), as
well as activation of TGF-β [96] and indoleamine 2,3-
dioxygenase (IDO) in colonic epithelial cells [89]. Intestinal
epithelial cells are crucial for the maintenance of innate
and adaptive immune homeostasis in the gut. Moreover,
even the colonization with altered Schaedler flora (ASF),
which includes Clostridium clostridioforme, leads to the ac-
cumulation of Tregs within the colon [97]. Consistent with
these findings, F. prausnitzii, which belongs to ClostridiumFood, Gut flora
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blood mononuclear cells in vitro [98]. How Tregs induced
by commensal Clostridia can contribute to immune
homeostasis in the intestine is an important question to
address. Foxp3+ cells with TCRs specific for CBir1, a fla-
gellin related to those of Clostridium cluster XIVa, in-
duce IgA+ B cells in the intestine in order to reduce the
mucosal uptake of microbiota-derived antigens and pre-
vent systemic T cell activation [99]. Therefore, Clostrid-
ium spp. can affect the number and function of colonic
Tregs, inducing naive CD4+ T cells to differentiate into
antigen-specific colonic Tregs that are able to enforce
immune tolerance towards commensal bacteria. It is in-
teresting to note that even conventional T cells express
TCRs specific for commensal antigens, and are poten-
tially colitogenic if not completely suppressed by intes-
tinal Tregs [100]. Notably, elevated levels of Clostridium
clusters XIVa and IV in mice leads to resistance to allergy
and intestinal inflammation in experimental models [89].
Conversely, the microbiota of individuals with chronic
inflammation show lower bacterial diversity and it has
been determined that Clostridium clusters IV, particularly
F. prausnitzii, and XIVa are significantly less abundant in
IBD patients compared to healthy subjects [14,98,101]. It
is still unknown whether the decrease in Clostridia is a
cause or a consequence of chronic inflammation in IBD
patients and in autoimmunity, but we can speculate that
they are necessary for immune homeostasis, contributing
to the suppression of autoimmunity and deleterious in-
flammation in humans.
Conclusions
The present review provides evidence that Clostridia,
contributing to a significant portion of indigenous bac-
teria in the large intestine, are strongly involved in the
maintenance of overall gut function. From an experi-
mental point of view, this thesis has been strongly
strengthened in a very recent paper [102]. Maurice et al.,
studying the role of xenobiotics in shaping the physi-
ology and gene expression of the active humane gut
microbiota, showed that a distinctive subset of microor-
ganisms, enriched for Clostridia, tends to dominate the
active fraction of the gut microbiota [102]. The position
of Clostridia, in close relationship with intestinal cells,
allows them to participate as crucial factors in modulat-
ing physiologic, metabolic and immune processes in the
gut (summarized in Figure 1), and appears to be neces-
sary for the welfare of maintaining normal gut immune
homeostasis and, on the basis of their influence on the
neuroenteric system, of the brain-gut axis. Based on this
new information, novel pathogenic hypotheses can be
formed that have important translational implications
in regard to the prevention and treatment of dysbiosis
that can be implicated in many gastrointestinal disorders,including chronic intestinal inflammation, colorectal can-
cer and irritable bowel syndrome. It will be fascinating to
elucidate the underlying mechanisms for xenobiotic resist-
ance and metabolism in the active human gut microbiota
in order to provide indications for unexplained patient-
to-patient variations in drug efficacy and toxicity. It will
also be important to perform detailed mechanistic studies
to improve the development of microbial therapies that
may modulate the composition of the gut microflora, cap-
italizing on the key role of commensal Clostridia, with the
end goal of promoting gut health.
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